Last kr507.00 SEK
Change Today +1.00 / 0.20%
Volume 63.5K
AZN On Other Exchanges
Symbol
Exchange
New York
Xetra
London
Stockholm
OTC US
Mexico
Berlin
As of 5:47 AM 07/14/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

Open
kr508.50
Previous Close
kr506.00
Day High
kr510.00
Day Low
kr506.00
52 Week High
05/2/14 - kr540.00
52 Week Low
08/15/13 - kr319.40
Market Cap
640.1B
Average Volume 10 Days
360.5K
EPS TTM
--
Shares Outstanding
1.3B
EX-Date
02/19/14
P/E TM
--
Dividend
kr2.98
Dividend Yield
3.99%
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. and FibroGen, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZN) Key Developments

AstraZeneca Enters into Research Agreement with Max Planck Institute of Molecular Physiology

AstraZeneca has entered into an agreement with Max Planck Institute of Molecular Physiology for the creation of a satellite unit in cardiovascular and metabolic disease, which will be geared towards research into "novel chemistry and chemical biology in areas of new modality chemistry, such as stabilized peptides, macrocycles, and conjugation chemistry. The research will focus on identifying novel targets within the areas of cardiac regeneration, islet health (diabetes), and diabetic nephropathy. The satellite unit is to be linked to the company's cardiovascular and metabolic disease innovative medicines unit (iMed) based in Molndal, Sweden.

Astrazeneca Announces Results of Two Pivotal Phase III Studies KODIAC-4 and KODIAC-5 of Naloxegol

AstraZeneca announced that the results of two pivotal Phase III studies KODIAC-4 and KODIAC-5 of naloxegol, an investigational treatment for opioid-induced constipation (OIC). Opioids play an important role in chronic pain relief by binding to mu-receptors in the brain, but they also bind to mu-receptors in the bowel. That is why patients taking opioids for chronic pain can develop OIC. In fact, the incidence of OIC varies and has been reported as high as 81% in patients taking opioids. Naloxegol, which has the potential to be the first FDA approved once-daily oral treatment for patients with OIC, is a peripherally-acting mu-opioid receptor antagonist (PAMORA) studied in adult patients with chronic non-cancer pain experiencing OIC. Primary endpoint data from the KODIAC-4 and -5 studies showed that more OIC patients treated with naloxegol 25 mg had a consistent response of increased spontaneous bowel movements (SBMs) through 12 weeks of treatment compared to placebo [44% vs. 29% (p=0.001 KODIAC-4) and 40% vs. 29% (p=0.021 KODIAC-5)]. The 12.5 mg dose in KODIAC-5 did not show statistical significance for the primary endpoint. The 25 mg dose also demonstrated a higher response rate through 12 weeks of treatment compared to placebo in patients with laxative inadequate response (LIR), a secondary endpoint. Results for an additional secondary endpoint showed that patients taking naloxegol 25 mg in the KODIAC-4 and KODIAC-5 studies were likely to have a first post-dose spontaneous bowel movement 25-30 hours sooner than placebo, respectively (median six and 12 hours for naloxegol 25 mg compared to 36 and 37 hours for placebo, in studies KODIAC-4 and -5, respectively).

Cepheid and AstraZeneca, Cubist Pharmaceuticals, Inc. and GSK Partner on A Diagnostic Test to Help Tackle Multidrug-Resistant Bacterial Infections

Cepheid announced a new collaboration with AstraZeneca, Cubist Pharmaceuticals Inc. and GSK intended to promote transformational change in infectious disease therapy by developing a rapid diagnostic test that can target multi-drug resistant pathogens and support the appropriate use of antibiotics. Targeting bacterial infections with the right treatment will slow the development of resistance that has led to a crisis in treating infections. Xpert Carba-R is a rapid test under development for use with rectal swab samples to identify the presence of potentially life threatening bacteria. Specifically, the consortium is working to extend the number of body sample types from rectal swabs to other body samples such as respiratory samples from patients with pneumonia. Xpert Carba-R is commercially available outside the US, and is targeted for commercial release in the US in 2015, subject to regulatory approval.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:SS kr507.00 SEK +1.00

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $54.96 USD -0.83
Bayer AG €101.80 EUR +0.59
Biogen Idec Inc $322.22 USD +3.10
Eli Lilly & Co $62.84 USD +0.31
Novo Nordisk A/S kr250.10 DKK +2.30
View Industry Companies
 

Industry Analysis

AZN

Industry Average

Valuation AZN Industry Range
Price/Earnings 45.7x
Price/Sales 3.6x
Price/Book 4.4x
Price/Cash Flow 45.9x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit www.astrazeneca.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.